System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
Screening methods for identifying Sp35 antagonists
US9068992B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9068992-B2 |
| Application number | US-201313802249-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2013 |
| Priority date | Jun 24, 2004 |
| Publication date | Jun 30, 2015 |
| Grant date | Jun 30, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of identifying an Sp35 antagonist capable of promoting oligodendrocyte-mediated myelination comprising contacting a co-culture of neurons and oligodendrocytes with a compound that binds to Sp35 or to a polynucleotide that encodes Sp35 and measuring myelination, wherein increased myelination compared to a control co-culture indicates the compound is an Sp35 antagonist capable of promoting oligodendrocyte-mediated myelination. 2. Th…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9068992B2 cover?
- The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.
- Who is the assignee on this patent?
- Biogen Idec Inc, Biogen Ma Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6893. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).